Baker RE, Mahmud AS, Miller IF, Rajeev M, Rasambainarivo F, Rice BL, et al. Infectious disease in an era of global change. Nat Rev Microbiol. 2022;20:193–205.

Article  CAS  PubMed  Google Scholar 

Bloom DE, Cadarette D. Infectious Disease threats in the twenty-first century: strengthening the global response. Front Immunol. 2019;10:549.

Article  PubMed  PubMed Central  Google Scholar 

Piret J, Boivin G. Pandemics throughout history. Front Microbiol. 2020;11:631736.

Article  PubMed  Google Scholar 

Wolfe ND, Dunavan CP, Diamond J. Origins of major human infectious diseases. Nature. 2007;447:279–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH, et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist. 2018;11:1645–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109:309–18.

Article  PubMed  PubMed Central  Google Scholar 

Larkin H. Increasing antimicrobial resistance poses global threat, WHO says. JAMA 2023;329:200.

PubMed  Google Scholar 

Cameron A, Esiovwa R, Connolly J, Hursthouse A, Henriquez F. Antimicrobial resistance as a global health threat: the need to learn lessons from the COVID-19 pandemic. Glob Policy. 2022;13:179–92.

Article  PubMed  PubMed Central  Google Scholar 

EclinicalMedicine. Antimicrobial resistance: a top ten global public health threat. EClinicalMedicine. 2021;41:101221.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Kraker ME, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050? PLoS Med. 2016;13:e1002184.

Article  PubMed  PubMed Central  Google Scholar 

Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629–55.

Article  Google Scholar 

Folkesson A, Jelsbak L, Yang L, Johansen HK, Ciofu O, Høiby N, et al. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat Rev Microbiol. 2012;10:841–51.

Article  CAS  PubMed  Google Scholar 

Jurado-Martin I, Sainz-Mejias M, McClean S. Pseudomonas aeruginosa: an audacious pathogen with an adaptable arsenal of virulence factors. Int J Mol Sci. 2021;22:3128.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qin S, Xiao W, Zhou C, Pu Q, Deng X, Lan L, et al. Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Signal Transduct Target Ther. 2022;7:199.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wood SJ, Kuzel TM, Shafikhani SH. Pseudomonas aeruginosa: infections, animal modeling, and therapeutics. Cells. 2023;12:199.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gellatly SL, Hancock RE. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis. 2013;67:159–73.

Article  CAS  PubMed  Google Scholar 

Lyczak JB, Cannon CL, Pier GB. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect. 2000;2:1051–60.

Article  CAS  PubMed  Google Scholar 

Yin R, Cheng J, Wang J, Li P, Lin J. Treatment of Pseudomonas aeruginosa infectious biofilms: challenges and strategies. Front Microbiol. 2022;13:955286.

Article  PubMed  PubMed Central  Google Scholar 

Davies O, Bennett S. WHO publishes list of bacteria for which new antibiotics are urgently needed. WHO Newsletters. 2017.

Jayaraman N, Mahapa A, Samanta G, Maiti K, Chatterji D. Mannopyranoside glycolipids inhibit mycobacterial growth, biofilm and potentiate isoniazid inhibition activities in M. smegmatis. ChemBioChem. 2019;20:1966–76.

Article  PubMed  Google Scholar 

Dolan SK. Current knowledge and future directions in developing strategies to combat Pseudomonas aeruginosa Infection. J Mol Biol. 2020;432:5509–28.

Article  CAS  PubMed  Google Scholar 

Verderosa AD, Totsika M, Fairfull-Smith KE. Bacterial biofilm eradication agents: a current review. Front Chem. 2019;7:824.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jangra V, Sharma N, Chhillar AK. Therapeutic approaches for combating Pseudomonas aeruginosa infections. Microbes Infect. 2022;24:104950.

Article  CAS  PubMed  Google Scholar 

Chatterjee M, Anju CP, Biswas L, Anil Kumar V, Gopi Mohan C, Biswas R. Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options. Int J Med Microbiol. 2016;306:48–58.

Article  CAS  PubMed  Google Scholar 

Schnappinger D. Genetic approaches to facilitate antibacterial drug development. Cold Spring Harb Perspect Med. 2015;5:a021139.

Article  PubMed  PubMed Central  Google Scholar 

Matano LM, Morris HG, Wood BM, Meredith TC, Walker S. Accelerating the discovery of antibacterial compounds using pathway-directed whole cell screening. Bioorg Med Chem. 2016;24:6307–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brotz-Oesterhelt H, Sass P. Postgenomic strategies in antibacterial drug discovery. Future Microbiol. 2010;5:1553–79.

Article  PubMed  Google Scholar 

Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10:507–19.

Article  CAS  PubMed  Google Scholar 

Lechartier B, Rybniker J, Zumla A, Cole ST. Tuberculosis drug discovery in the post-post-genomic era. EMBO Mol Med. 2014;6:158–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miethke M, Pieroni M, Weber T, Bronstrup M, Hammann P, Halby L, et al. Towards the sustainable discovery and development of new antibiotics. Nat Rev Chem. 2021;5:726–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boyd NK, Teng C, Frei CR. Brief overview of approaches and challenges in new antibiotic development: a focus on drug repurposing. Front Cell Infect Microbiol. 2021;11:684515.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao X, Lam JS. WaaP of Pseudomonas aeruginosa is a novel eukaryotic type protein-tyrosine kinase as well as a sugar kinase essential for the biosynthesis of core lipopolysaccharide. J Biol Chem. 2002;277:4722–30.

Article  CAS  PubMed  Google Scholar 

Sarkar B, Mahapa A, Dey K, Manhas R, Chatterji D, Jayaraman N. Aza-Michael promoted glycoconjugation of PETIM dendrimers and selectivity in mycobacterial growth inhibitions. RSC Adv. 2023;13:4669–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nadri MH, Salim Y, Basar N, Yahya A, Zulkifli RM. Antioxidant activities and tyrosinase inhibition effects of Phaleria macrocarpa extracts. Afr J Tradit Complement Alter Med. 2014;11:107–11.

Article  Google Scholar 

Clinical, Institute LS. Performance standards for antimicrobial susceptibility testing. Wayne, PA: Clinical and Laboratory Standards Institute; 2017. p. 106–12.

Mahapa A, Samanta GC, Maiti K, Chatterji D, Jayaraman N. Mannopyranoside glycolipids inhibit mycobacterial and biofilm growth and potentiate isoniazid inhibition activities in M. smegmatis. ChemBioChem. 2019;20:1966–76.

Article  CAS  PubMed  Google Scholar 

Lambert RJ, Pearson J. Susceptibility testing: accurate and reproducible minimum inhibitory concentration (MIC) and non-inhibitory concentration (NIC) values. J Appl Microbiol. 2000;88:784–90.

Article  CAS  PubMed  Google Scholar 

Van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT assay. Methods Mol Biol. 2011;731:237–45.

Standards NCfCL, Barry AL. Methods for determining bactericidal activity of antimicrobial agents: approved guideline. Wayne, PA: National Committee for Clinical Laboratory Standards; 1999.

Maiti K, Syal K, Chatterji D, Jayaraman N. Synthetic arabinomannan heptasaccharide glycolipids inhibit biofilm growth and augment isoniazid effects in mycobacterium smegmatis. ChemBioChem. 2017;18:1959–70.

Article  CAS  PubMed  Google Scholar 

Caiazza NC, Shanks RM, O’toole G. Rhamnolipids modulate swarming motility patterns of Pseudomonas aeruginosa. J Bacteriol. 2005;187:7351–61.